All In Biotech

Drug Trial Radar · NCT01081769

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics

A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Feb 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 769 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

769

Actual

Start

Feb 2010

Primary completion

Feb 2013

Study completion Feb 2013

Sponsor

Lead sponsor
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered antipsychotics in monotherapy over 24 months in the treatment of recently diagnosed (1-5 years since diagnosis) schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • paliperidone palmitate injectionDrug

    injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter

  • oral antipsychoticsDrug

    daily treatment according to local label for maximally 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Relapse EventTime frame: from baseline (Day 1 of core phase) up to maximally 24 months.
  2. Number of Participants With a Relapse EventTime frame: from baseline (Day 1 of core phase) up to maximally 24 months

Locations

94 sites in 25 countries. Site status is shown where the registry gives one.

  • Site not named

    Vienna, Austria

  • Site not named

    Bertrix, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Ostend, Belgium

  • Site not named

    Burgas, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Radnevo, Bulgaria

  • Site not named

    Zagreb, Croatia

  • Site not named

    Brno, Czechia

  • Site not named

    Litoměřice, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Přerov, Czechia

  • Site not named

    Alexandria, Egypt

  • Site not named

    Cairo, Egypt

  • Site not named

    Talinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Colombes, France

  • Site not named

    La Seyne-sur-Mer, France

  • Site not named

    Limoges, France

  • Site not named

    Metz, France

  • Site not named

    Paris, France

  • Site not named

    Saint-Avé, France

  • Site not named

    Berlin, Germany

  • Site not named

    Bochum, Germany

  • Site not named

    Mannheim, Germany

  • Site not named

    München, Germany

  • Site not named

    Thessalonikis, Greece

  • Site not named

    Budapest, Hungary

  • Site not named

    Kalocsa, Hungary

  • Site not named

    Nagykálló, Hungary

  • Site not named

    Sopron, Hungary

  • Site not named

    Bat Yam, Israel

  • Site not named

    Beer Yaakov, Israel

  • Site not named

    Hod HaSharon, Israel

  • Site not named

    Ramat Gan, Israel

  • Site not named

    Tirat Hacarmel, Israel

  • Site not named

    Amman, Jordan

  • Site not named

    Šiauliai, Lithuania

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.